Education and Training Strategy

Similar documents
Chemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines

NATIONAL CANCER CONTROL PROGRAMME. Oral Anti-Cancer Medicines Model of Care Recommendations

1. Intrathecal must never be abbreviated to IT on a prescription form True / False

Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.

National Cancer Peer Review Programme. Radiotherapy Service Evidence Guide

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY

A themed review of patient safety incidents involving anti-cancer medicines 1 November June 2008

ECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1

SUBSPECIALIST TRAINING PROGRAMME

Guidelines for the appointment of. General Practitioners with Special Interests in the Delivery of Clinical Services. Epilepsy

POLICY FOR INTRATHECAL CYTOTOXIC CHEMOTHERAPY

POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011

Guidance for the Network Review of Chemotherapy Errors

Policy for the safe use of oral methotrexate

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

Panel Discussion: Orals Adherence & Challenges Friday, April 28 th, 2017

Guidance for Pharmacists on Safe Supply of Oral Methotrexate

Psychotherapeutic Counselling and Intersubjective Psychotherapy College (PCIPC)

ROLE SPECIFICATION FOR MACMILLAN GPs

Using MiCAL v18 (Medicines Information Computer Aided Learning) effectively

e Scottish Diabetic Retinopathy Screening Programme

QA Processes. Philip DaCosta BSCP QA Lead, Yorkshire & the Humber September 2013

National Cancer Peer Review Programme

The Professional Relationships Associated with the Practice of Dental Therapy Practice Standard

Training in palliative and end-of-life care: Guidance for trainees (and their trainers) in non-palliative medicine training posts

Guidelines for the use of G-CSF in the Department of Oncology

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

COMPETENCES REQUIRED FOR APPLICANTS TO ATTAIN HPC REGISTRATION AS CLINICAL SCIENTISTS

Table 1 Standards and items to set up a PCU: general requirements and critical mass

Faculty of Social Sciences

Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Version No. 1.1 Supercedes 1.0 Links to other policies

Safe handling of oral anticancer agents

ISO and the Delivery of Competent NDT Services

Training in Gynaecological Oncology LOG BOOK

Response to. GPhC Consultation. Guidance to ensure a safe and effective pharmacy team.

Primary Health Networks

Specialist List in Special Care Dentistry

What is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015

UKAS Guidance on the Application of ISO/IEC Dealing with Expressions of Opinions and Interpretations

dietitian? nutritionist?

Supervisor Handbook for the Diploma of Diagnostic Ultrasound (DDU)

Substance use and misuse

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

Dear Colleague GENERAL OPHTHALMIC SERVICES OPTOMETRY INDEPENDENT PRESCRIBING. Summary

Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business

Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception

Programme Specification

PRESCRIBING BY RADIOGRAPHERS: A VISION PAPER

OPCS Classification of Interventions and Procedures Version 4.6 (April 2011)

Trust Policy 218 Ionising Radiation Safety Policy

Commissioning Chemotherapy Services Conference. Issues of consent in systemic therapy

Health and Safety Policy Arrangements: Radiation Protection Guidelines

Registrar Palliative Medicine

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1

Reference No: SG 23/13

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

Document ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy

NRT Voucher redemption scheme service specification

Enhanced Continuing Professional Development and Personal Development Planning

CERTIFICATE IN SPECIAL CARE DENTAL NURSING

A critical appraisal of: Canadian guideline fysisk aktivitet using the AGREE II Instrument

Additional information to support. The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines

ACTION PLAN FOLLOWING THE LUNG CANCER PEER REVIEW

Diploma in Implant Dentistry Opportunities 2014

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

Knowledge Based Qualification for the NVQ3 (QCF) Diploma in Pharmacy Service Skills. Master Forms

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Drug Misuse and Dependence Guidelines on Clinical Management

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Oncology Programme 2017

ERS School and postgraduate education

An Integrated National Strategy for Breast Cancer Audit. Martin Lee Gill Lawrence

Clinical Pharmacology and Therapeutics

All Wales Lymphoedema Service and Community Pharmacy Wales Collaborative Project Terms of Reference (ToR)

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )

The legally binding text is the original French version

Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference

SPECIAL ARTICLES Graduate Programs in Advanced Pharmacy Practice in Oncology in Japan

NA-019 LEVEL 3 QUALIFICATION RECOGNITION FOR AS3669 AND EN 4179 / NAS 410

ADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME

UNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

Brighton and Hove Pharmacy Enhanced Service (PLES 02)

National Prostate Cancer Audit. Bill Cross June 2015

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian

Referral guide for acute oncology emergencies

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report

FAQ Document for Guidance on the Safe Use of Intrathecal Chemotherapy in the Treatment of Cancer

PATIENT GROUP DIRECTIONS POLICY

Lung Cancer MCN Work Plan 2017/18

Ruth Howkins Deputy National Coordinator National Cancer Peer Review

Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes

Nab-Paclitaxel (Abraxane) and Gemcitabine For Pancreatic Adenocarcinoma Cumbria, Northumberland, Tyne & Wear Area Team

Guidance for CPD Providers. Information and help for organisations providing CPD for chiropractors

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE

Management of AIDS/HIV Infected Healthcare Workers Policy

Guideline for the Follow-up of Patients with Gynaecological Malignancies

South Tees Hospitals NHS Foundation Trust. Excellence in dementia care across general hospital and community settings. Competency framework

Transcription:

ECN Pharmacy Group Education and Training Strategy Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document relates: Approved by: Date approved: Next Review date: Lead Pharmacist, ECN Pharmacy required ECN Oncology Pharmacy Group Cancer pharmacy staff within ECN ECN Oncology Pharmacy Group and ratified by ECN MM Board Version No: 3 Responsibility for review: Lead Pharmacist, Essex Cancer Network Page 1 of 6

Contents Scope... 3 Introduction... 3 Definition of Prescription Verification... 3 Principles for All... 3 Principles for Level One Training... 4 Knowledge... 4 Training... 4 Key elements of syllabus... 4 Revalidation... 4 Principles for Level Two Training... 4 Knowledge... 4 Training... 4 Principles for Level Three Training... 5 Knowledge... 5 Post graduate Education... 5 Revalidation... 5 To be covered in annual appraisal... 5 Competencies for verification... 5 Approved list... 6 Competences... 6 The RPS and BOPA are working together to produce a set of competences for oncology pharmacists. Once these are published this document will be reviewed.... 6 Page 2 of 6

Scope This strategy has been developed to ensure that there is a baseline requirement for training for all pharmacy staff within ECN. This guidance applies to parenteral and oral administration of SACT including chemotherapy and non-cytotoxic medicines such as targeted therapies, antibody treatments and novel therapies, e.g. rituximab, sunitinib and lenalidomide Introduction The Department of Health requires that all chemotherapy prescriptions should be checked and authorised by a pharmacist The National Cancer Action Team report into the Quality and Safety of Chemotherapy Services published in August 2009 states All chemotherapy prescriptions should be checked by an oncology pharmacist, who has undergone specialist training, demonstrated their appropriate competence and is locally authorised/ accredited for the task. This strategy sets out to explain how this will be achieved within ECN. Definition of Prescription Verification Prescription verification describes what key steps a pharmacist must take when checking prescriptions for anticancer medicines. It is recognised that the there are other terms in common use to describe this process e.g. clinical checking, screening or validation etc Principles for All All new staff should complete an oncology pharmacy training programme. This will be targeted to one of the three levels below depending on their role. o Level One: For any staff who may come across chemotherapy in their normal job, such as dispensary technicians, assistants and aseptics staff. o Level Two: For all staff involved in prescription verification of SACT prescriptions o Level Three: For specialist oncology staff, who work within the area of cancer for more than 50% of their time, or are designated as a cancer specialist at their trust. All pharmacy staff should undertake Continuing Professional Development (CPD). In order to support dispensary staff involved in the dispensing and supply of oral anticancer medicines, there must always be available in the organisation a trained oncology pharmacist who is able to provide oncology pharmacy advice to dispensary staff. Further work is ongoing in defining specific educational competencies outlining the knowledge and understanding that an appropriately trained pharmacist verifying a prescription must have. Guidance will be sought from BOPA / new Professional Leadership Body (PLB) in setting the standards for cancer pharmacy. A single pharmacist trained to level two or three must be identifiable as having verified the prescription. This is separate to a final check undertaken by another person (who can be trained to level one, two or three). Page 3 of 6

Principles for Level One Training Knowledge Basic background knowledge of cancer Training One hour lunchtime session held each year. The network will provide a presentation to the designated oncology pharmacists in each trust to base their training on. Key elements of syllabus Health and safely/ safe handling Relevant protocols/sops to trust Labelling Counselling Where to go for further advice Background and principles of chemotherapy Revalidation To be revalidated the individual must attend a yearly update in oncology training session. Principles for Level Two Training Knowledge Basic level of understanding of the principles involved in treating the more common forms of cancer Knowledge of common side effects and how to treat them Training Training with a level three pharmacist or experience level 2 pharmacist if deemed competent by level 3 pharmacist: Training must include the following: o Principles of treatment (neoadjuvant to palliative), cell cycle kill o Surgery, radiotherapy and chemotherapy o How common classes of chemotherapy agents work cell cycle, targeted therapies o Common side effects and management o Counselling o Where to go for further advice o Basic role of Cancer Network A period of supervised verification of chemotherapy prescriptions. o During this period all prescriptions should be double checked by a level three pharmacist (or level 2 were appropriate) and a log sheet kept of a min 50 chemotherapy items (30 prescriptions for Basildon Hospital). These must include a variety of different prescriptions that reflect local case mix It is the responsibility of level 3 pharmacist to ensure that all training has been completed and that level 2 pharmacists are competent. The network will provide a level 2 training document to the designated oncology pharmacists in each trust to base their training on. Page 4 of 6

To maintain competency, level 2 pharmacists must keep a log of at least 20 prescriptions verification every 6 months (10 prescriptions for Trusts who treat haematology patients only) These should reflect local case mix. Revalidation Annually: To remain on the approved list, the individual must satisfy a level three pharmacist that they are competent. If this is not possible, then either a period of supervised verification of chemotherapy prescriptions or mock test is to be completed. Principles for Level Three Training Knowledge In depth knowledge of the treatment and support of patients with a wider range of cancers Post graduate Education Expected to undertake CPD and further training to ensure up to date in current oncology issues. Opportunities for achieving this may include: Oncology module in a post graduate diploma in clinical pharmacy MSc Oncology whole or selected modules Attendance at BOPA symposium Revalidation To be covered in annual appraisal Competencies for verification 1. Demonstrates understanding of the biology of cancer including classification, mechanism of action and scheduling of systemic therapy and disease progression. 2. Demonstrates understanding/ knowledge all regimens used within scope of practice. 3. An in-depth understanding of principles of chemotherapy and SACT and the mechanism of actions / pharmacology of drugs used. 4. Knows how to access local regimen /protocol information and check if regimen/ protocol is approved for use. 5. Demonstrates understanding of key roles of the local multidisciplinary oncology, haematology teams and structure of local cancer services 6. Demonstrates understanding of common terminology used in cancer, staging systems, tumour markers, and performance status. 7. Demonstrates ability to accurately verify chemotherapy prescriptions within scope of practice. 8. Demonstrates understanding/ knowledge of management of common toxicities of cancer treatment. 9. Demonstrates understanding/ knowledge of management of common symptoms/complications of cancer treatments e.g. mucositis, neutropenia, nausea and vomiting, etc. to a depth appropriate to the regimens in use. 10. Demonstrates understanding/ knowledge of the impact of cancer on the patient and their family. i.e. need to be able to communicate sensitively about the prescription they have verified. 11. Demonstrates understanding/ knowledge of systemic therapy dose calculations including body surface area (BSA) determination. Page 5 of 6

Approved list Each trust will have an approved list of designated pharmacists who are competent to verify cancer medicine prescriptions (level two or three pharmacist) which is maintained by the clinical lead responsible for cancer services. Competences The RPS and BOPA are working together to produce a set of competences for oncology pharmacists. Once these are published this document will be reviewed. Page 6 of 6